These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38840122)

  • 1. The impact of colistin-based regimens on mortality compared to other antimicrobials in patients with carbapenem-resistant Enterobacterales bacteremia in South African hospitals: a cross-sectional study.
    Ngoma N; Perovic O; de Voux A; Musekiwa A; Shuping L;
    BMC Infect Dis; 2024 Jun; 24(1):561. PubMed ID: 38840122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carbapenem-resistant Enterobacterales in patients with bacteraemia at tertiary academic hospitals in South Africa, 2019 - 2020: An update.
    Lowe M; Shuping L; Perovic O
    S Afr Med J; 2022 Aug; 112(8):542-552. PubMed ID: 36214398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emergence and expansion of carbapenem resistant enterobacterales in the Western Cape Province, South Africa.
    Moloto K; Newton-Foot M; Whitelaw A; Dramowski A
    PLoS One; 2024; 19(8):e0309315. PubMed ID: 39186516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carbapenem-resistant Enterobacteriaceae in patients with bacteraemia at tertiary hospitals in South Africa, 2015 to 2018.
    Perovic O; Ismail H; Quan V; Bamford C; Nana T; Chibabhai V; Bhola P; Ramjathan P; Swe Swe-Han K; Wadula J; Whitelaw A; Smith M; Mbelle N; Singh-Moodley A;
    Eur J Clin Microbiol Infect Dis; 2020 Jul; 39(7):1287-1294. PubMed ID: 32124106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood stream infections due to OXA-48-like carbapenemase-producing Enterobacteriaceae: treatment and survival.
    Balkan II; Aygün G; Aydın S; Mutcalı SI; Kara Z; Kuşkucu M; Midilli K; Şemen V; Aras S; Yemişen M; Mete B; Özaras R; Saltoğlu N; Tabak F; Öztürk R
    Int J Infect Dis; 2014 Sep; 26():51-6. PubMed ID: 24998423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mortality factors and antibiotic options in carbapenem-resistant Enterobacterales bloodstream infections: Insights from a high-prevalence setting with co-occurring NDM-1 and OXA-48.
    Karnmueng P; Montakantikul P; Paiboonvong T; Plongla R; Chatsuwan T; Chumnumwat S
    Clin Transl Sci; 2024 Jun; 17(6):e13855. PubMed ID: 38853376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment options and clinical outcomes for carbapenem-resistant Enterobacteriaceae bloodstream infection in a Chinese university hospital.
    Li C; Li Y; Zhao Z; Liu Q; Li B
    J Infect Public Health; 2019; 12(1):26-31. PubMed ID: 30145151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Carbapenem-resistant
    Ruvinsky S; Voto C; Roel M; Deschutter V; Ferraro D; Aquino N; Reijtman V; Galvan ME; Motto E; García M; Sarkis C; Bologna R
    Front Public Health; 2022; 10():983174. PubMed ID: 36091556
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors and outcomes associated with the isolation of polymyxin B and carbapenem-resistant Enterobacteriaceae spp.: A case-control study.
    Teo JQ; Chang CW; Leck H; Tang CY; Lee SJ; Cai Y; Ong RT; Koh TH; Tan TT; Kwa AL
    Int J Antimicrob Agents; 2019 May; 53(5):657-662. PubMed ID: 30880229
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retrospective Observational Study from a Chinese Network of the Impact of Combination Therapy versus Monotherapy on Mortality from Carbapenem-Resistant
    Wang X; Wang Q; Cao B; Sun S; Zhang Y; Gu B; Li B; Liao K; Zhao F; Jin L; Jin C; Yang C; Pei F; Zhang Z; Wang H
    Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30348660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing the Outcomes of Patients With Carbapenemase-Producing and Non-Carbapenemase-Producing Carbapenem-Resistant Enterobacteriaceae Bacteremia.
    Tamma PD; Goodman KE; Harris AD; Tekle T; Roberts A; Taiwo A; Simner PJ
    Clin Infect Dis; 2017 Feb; 64(3):257-264. PubMed ID: 28013264
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparing mortality in patients with carbapenemase-producing carbapenem resistant Enterobacterales and non-carbapenemase-producing carbapenem resistant Enterobacterales bacteremia.
    Hovan MR; Narayanan N; Cedarbaum V; Bhowmick T; Kirn TJ
    Diagn Microbiol Infect Dis; 2021 Dec; 101(4):115505. PubMed ID: 34399381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effectiveness and mortality of colistin monotherapy versus colistin-fosfomycin combination therapy for the treatment of carbapenem-resistant Enterobacteriaceae (CRE) infections: A propensity score analysis.
    Katip W; Rayanakorn A; Oberdorfer P; Taruangsri P; Nampuan T; Okonogi S
    J Infect Public Health; 2024 May; 17(5):727-734. PubMed ID: 38513335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae.
    van Duin D; Lok JJ; Earley M; Cober E; Richter SS; Perez F; Salata RA; Kalayjian RC; Watkins RR; Doi Y; Kaye KS; Fowler VG; Paterson DL; Bonomo RA; Evans S;
    Clin Infect Dis; 2018 Jan; 66(2):163-171. PubMed ID: 29020404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin versus polymyxin B for the treatment of carbapenem-resistant Klebsiella pneumoniae bloodstream infections.
    Vieceli T; Henrique LR; Rech TH; Zavascki AP
    J Infect Chemother; 2024 Jul; 30(7):621-625. PubMed ID: 38244722
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment and Outcome of Carbapenem-Resistant Gram-Negative Bacilli Blood-Stream Infections in a Tertiary Care Hospital.
    Shah PG; Shah SR
    J Assoc Physicians India; 2015 Jul; 63(7):14-8. PubMed ID: 26731822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid Increase in Prevalence of Carbapenem-Resistant Enterobacteriaceae (CRE) and Emergence of Colistin Resistance Gene
    Li Y; Sun QL; Shen Y; Zhang Y; Yang JW; Shu LB; Zhou HW; Wang Y; Wang B; Zhang R; Wang S; Shen Z
    J Clin Microbiol; 2018 Apr; 56(4):. PubMed ID: 29386265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Excess Mortality Associated With Colistin-Tigecycline Compared With Colistin-Carbapenem Combination Therapy for Extensively Drug-Resistant Acinetobacter baumannii Bacteremia: A Multicenter Prospective Observational Study.
    Cheng A; Chuang YC; Sun HY; Sheng WH; Yang CJ; Liao CH; Hsueh PR; Yang JL; Shen NJ; Wang JT; Hung CC; Chen YC; Chang SC
    Crit Care Med; 2015 Jun; 43(6):1194-204. PubMed ID: 25793437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiology of Carbapenem-Resistant Enterobacteriaceae Infections: Report from the China CRE Network.
    Zhang Y; Wang Q; Yin Y; Chen H; Jin L; Gu B; Xie L; Yang C; Ma X; Li H; Li W; Zhang X; Liao K; Man S; Wang S; Wen H; Li B; Guo Z; Tian J; Pei F; Liu L; Zhang L; Zou C; Hu T; Cai J; Yang H; Huang J; Jia X; Huang W; Cao B; Wang H
    Antimicrob Agents Chemother; 2018 Feb; 62(2):. PubMed ID: 29203488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome.
    de Maio Carrilho CM; de Oliveira LM; Gaudereto J; Perozin JS; Urbano MR; Camargo CH; Grion CM; Levin AS; Costa SF
    BMC Infect Dis; 2016 Nov; 16(1):629. PubMed ID: 27809803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.